Even skilled, experienced dermatologists make incorrect judgments when examining lesions on the skin to see if they are benign or malignant skin cancer, and these errors can lead to a delay of necessary treatment. AI Medical’s intelligent software Dermalyser is designed to diagnose a lesion in an instant with accuracy equal or superior to expert dermatologists.
Despite extensive training and experience, no doctor is infallible. In the field of dermatology, one of the most critical decisions made about a patient is whether a visible skin lesion is benign or malignant skin cancer. The consequences of a false-positive or a false-negative can range from disconcerting to devastating, and Christoffer Ekström, CEO of Swedish start-up AI Medical Technology, is personally familiar with the impact of both outcomes.